Sentences with phrase «over dividend payers»

There's another reason why folks are all over the dividend payers, and that's because of the outperformance over time.

In other words dividend growth provided an insignificant edge over dividend payers more generally.

We see equities remaining the dominant source of income going forward, though we prefer dividend growers — companies that increase their payout to shareholders — over dividend payers in this environment.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

We have about $ 650k in cash (which we use to buy & refurb small properties) the aforementioned $ 800k which is a nice mix of tech and F500 dividend payers, and just over $ 1M of retirement accounts - 750 in USA in appl, AMZN, GOOG etc, and $ 260K in UK where I worked for 12 years — BTW the $ 260K was $ 300K pre-Brexit.

With over a $ 200 billion dollar backlog of orders, the company is on track to get back its status as a blue chip dividend payer.

In contrast to high dividend payers, they tend to be more reasonably valued and have more potential to sustainably grow dividends over time.

I built a portfolio of about 60 dividend payers all producing between 4 and 7 points for an overall cash flow of about 6 and a half, or a little over 30k a year, without having to sell shares.

Over the long term, dividend - paying stocks have delivered higher returns with lower risk than non-dividend payers.

Despite not great financial results over the past 18 months, MCD has been an example in terms of dividend payer.

Many of the top performing dividend payers in the technology sector over the past six months, such as Badger Meter (NYSE: BMI) and Nam...

And yet we've seen in the last two posts that there's no compelling rationale for preferring a dividend index portfolio over an all - market portfolio composed of low - cost index ETFs that aren't biased toward dividend payers.

One, the prices of dividend stocks tend to be less volatile over time than non-dividend payers or «growth» stocks.

I built a portfolio of about 60 dividend payers all producing between 4 and 7 points for an overall cash flow of about 6 and a half, or a little over 30k a year, without having to sell shares.

Instead, choose reliable dividend - payers that can maintain those dividends even in bad times, while also growing them consistently over time.

Those with smaller portfolios can begin with a small collection of dividend payers and then slowly add stocks over the course of many years.

Over the long term, dividend - paying stocks have delivered higher returns with lower risk than non-dividend payers.

Favor dividend payers over nondividend payers.

We looked at data between 1978 and 2014 to find that dividend payers in the S&P 500 Index have historically outperformed non-dividend payers over the long term and have done so with less volatility.

Over time, companies that have initiated and / or increased their dividends have historically tended to outperform nondividend payers or stable dividend payers.

Later, the fast growing dividend payers take over, increasing income much faster than inflation.

My last post was devoted to dividend stocks with pep, which highlighted dividend payers that have outperformed over the last year.

I find myself with great dividend payers, but have found that my sector weighting is very unconventional.For example 5 % Healthcare & 5 % tech, being 23, I feel that those sectors are going to grow year over year in my lifetime but only hold a small holding so far.

If you were to exclude low dividend payers and non dividend payers, you would have well over 100 stocks to choose from.

Despite not great financial results over the past 18 months, MCD has been an example in terms of dividend payer.

As you might expect (because we're talking about investing in some of the best companies around), dividend payers and growers (like those we're talking about) tend to outperform the broader market over the long run.

Over the same period, dividend payers in developed markets fluctuated between 60 % and 70 % of companies.

It has a rocking chart since its inspection, its a dividend payer stock, its a stock that had increased its dividend over the years, its a company that been around for many years and that had survived the 2008 stock crash and now exceed the value of the before 2008 crash....

In spite of the setback during the period, the equity component of the Fund continues to focus on large cap dividend payers, which we believe possess significant competitive advantages over the long term.